buventol easyhaler inhalatsioonipulber
orion corporation - salbutamool - inhalatsioonipulber - 200mcg 1annus 200annus 1tk
buventol easyhaler inhalatsioonipulber
orion corporation - salbutamool - inhalatsioonipulber - 100mcg 1annus 200annus 1tk
biseptol tablett
pharmaceutical works polfa in pabiance joint stock co - sulfametoksasool+trimetoprim - tablett - 100mg+20mg 20tk
biseptol tablett
pharmaceutical works polfa in pabiance joint stock co - sulfametoksasool+trimetoprim - tablett - 800mg+160mg 10tk
biseptol tablett
pharmaceutical works polfa in pabiance joint stock co - sulfametoksasool+trimetoprim - tablett - 400mg+80mg 28tk; 400mg+80mg 20tk
biseptol infusioonilahuse kontsentraat
warsaw pharmaceutical works polfa s.a. - sulfametoksasool+trimetoprim - infusioonilahuse kontsentraat - 80mg+16mg 1ml 5ml 10tk
biseptol tablett
adamed pharma s.a. - sulfametoksasool+trimetoprim - tablett - 800mg+160mg 10tk
biseptol tablett
adamed pharma s.a. - sulfametoksasool+trimetoprim - tablett - 400mg+80mg 28tk
veklury
gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.